"I actually think that cancer tries to evolve, it tries to trick the body. Going about it one way is not the best way, we should have a tool of arsenals. That’s why we are really excited about this approach, because the mechanism and the way we are doing it is so different. It is meant to be useful on its own but also potentially complementary to whatever is out there. Our goal is not to make another approach redundant. What we are trying to do is create this extra vertical option that could be complementary with other treatments in the future against cancer." - Joshua Wang, Founder and CEO of VerImmune" - Joshua Wang
"Cancer doesn't happen overnight, it develops over time. Sometimes a cell changes so much that the body sees it as foreign, and that is when the immune system responds. It is like the police of your body. But cancer is also a disease of the self, when your own cells go bad, and from day one your immune system has been trained not to attack you but to protect you from yourself." - Joshua Wang, Founder and CEO of VerImmune" - Joshua Wang
"Let’s say you are a VC funder. You have a risk profile and need to deliver returns to LPs. Do you take a risk on a founder-led company, or on a VC-backed venture-created company with capital support if things go wrong and a three-time exit CEO leading it? Those are the stakes early-stage companies now face, and that is the new competition and normal we have to fight with." - Joshua Wang, Founder and CEO of VerImmune" - Joshua Wang
In this episode, Jeremy Au speaks on reprogramming cancer, biotech's funding shift, and why AI will rewrite biology.
Keywords: Joshua Wang, Reprogramming Cancer, Biotech Funding Shift, Why AI Will Rewrite Biology, Singapore, Southeast Asia, Healthcare, Artificial Intelligence, Founder Story
